Fertility test can be used to detect ovulation and/or to diagnose infertility, an inability to reproduce by natural means. It is done by both men and women to assess their fertility and various conditions associated with it. Both men and women experience fertility problems at about the same rate, but women are known to be more concerned about fertility testing.
Declining fertility rates among men and women, increasing awareness among people about fertility testing devices, increasing demand or adoption of fertility testing devices, and growing prevalence of PCOS (Polycystic Ovary Syndrome) among women are major factors expected to augment the growth of the global fertility testmarket during the forecast period.
For instance, globally, the fertility has fallen from an average of 5 births per woman in 1950 to 2.3 births per woman in 2021, an indication of the increasing control that people are able to exercise over their reproductive lives. According to the United Nation's World Population Prospects 2022 (WPP) report, the global fertility rate, which stood at 2.3 overall in 2021, will hit the demographic tipping point of 2.1 by 2050, due to a globally synchronized decline in birth rates.
Moreover, according to the latest population projections issued by Eurostat, the EU's population will decrease by 6% between 1 January 2022 and 1 January 2100, equivalent to 27.3 million fewer people. A birth rate declined across the European Union in 2020, hitting a 60-year low of 4 million births, according to data published by Eurostat in April 2022.
- This report provides in-depth analysis of the global fertility testmarket, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global fertility testmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Advacare Pharma, UEBE Medical, Abbott Laboratories, Quidel Corporation, HiLin Life Products Inc., Geratherm Medical AG, Fertility Focus Limited, Fairhaven Health LLC, Church & Dwight Co. Inc., and Prestige Brands Holdings Inc., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global fertility testmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fertility testmarket.
-
- Ovulation Prediction Kit
- Fertility Monitors
- Urine-based Ovulation Monitors
- Saliva-based Ovulation Monitors
- Other Fertility Monitors
- Male Fertility Testing Products
-
- OTC-based Products
- Prescription-based Products
-
- Female Fertility Testing
- Male Fertility Testing
-
- Home Care Setting
- Hospitals/Fertility Testing
-
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
-
- Advacare Pharma
- UEBE Medical
- Abbott Laboratories
- Quidel Corporation
- HiLin Life Products Inc.
- Geratherm Medical AG
- Fertility Focus Limited
- Fairhaven Health LLC
- Church & Dwight Co. Inc.
- Prestige Brands Holdings Inc.